Bullish indicating open at $55-$60, IPO prices at $37
Scott Dreyer, the Executive Vice President and Chief Commercial Officer of Collegium Pharmaceutical , Inc. (NASDAQ:COLL), a pharmaceutical company currently valued at $961 million and maintaining a "GREAT" financial health score according to InvestingPro, has recently sold shares in the company, according to a filing with the Securities and Exchange Commission. The transactions, executed under a pre-established Rule 10b5-1 trading plan, took place on March 20 and 21, 2025.
On March 20, Dreyer sold 1,927 shares at a weighted average price of $30.0005 per share. The following day, he sold an additional 18,881 shares at a weighted average price of $30.0293 per share. The total value of these transactions amounted to $624,794, with share prices ranging from $30.00 to $30.48.
Following these sales, Dreyer now directly owns 103,613 shares of Collegium Pharmaceutical. The sales were part of a plan adopted on August 28, 2024, allowing for the systematic selling of shares without breaching insider trading laws. While this insider sale has occurred, InvestingPro analysis reveals the company’s strong fundamentals, with 8 additional key insights and metrics available to subscribers, including details on management’s share buyback program and earnings growth projections.
In other recent news, Collegium Pharmaceuticals reported impressive fourth-quarter 2024 earnings, exceeding analyst expectations with an earnings per share of $1.75 compared to the forecasted $1.66. The company also surpassed revenue projections, posting $181.9 million against the anticipated $179.48 million. This strong performance was driven by robust demand for its ADHD medication, Jornay, and pain management products, BELBUCA and Xtampza ER. H.C. Wainwright maintained a Buy rating on Collegium, with a price target of $50, highlighting the company’s valuation and future performance despite potential generic competition. Additionally, Collegium announced significant changes to its Board of Directors and executive team as part of a strategic refreshment and succession planning initiative. Gino Santini is set to become the new Chairman of the Board, while Dr. Carlos Paya has been nominated for election. The company has also appointed David Dieter as Executive Vice President and General Counsel. These developments reflect Collegium’s ongoing commitment to governance and management excellence as it aligns its strategic direction with the evolving pharmaceutical landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.